Beta-2-Microglobulin (B2M) is used to evaluate the prognosis of patients with multiple myeloma.
Gold serum separator (SST) tube
Refrigerated (preferred) - 7 days
0.8 - 2.34 µg/mL
Serum levels are elevated in diseases associated with increased cell turnover. In multiple myeloma, B2M is a powerful prognostic factor and values <4 ìg/mL are considered a good prognostic indicator. Studies have shown that the median survival of patients with B2M values >4 ìg/mL was approximately 1 year, whereas median survival for patients with B2M values <4 ìg/mL was approximately 3.75 years.
Beta-2-Microglobulin is also elevated in chronic inflammation, liver disease, renal dysfunction, some acute viral infections, and a number of malignancies, especially hematologic disorders associated with the B-lymphocytes.
In renal tubular disease, serum B2M levels are low and urine levels are high.